Beauty Launchpad

DECEMBER 5, 2024

James Charles, with 20M+ followers, nailed his Daphne Blake Halloween look using Megalook Hair! Bold colors, 100% human hair, breathable caps, easy wear, and affordable prices make Megalook a top choice for influencers and style lovers.

90

90

Dermatology Times

DECEMBER 5, 2024

Dena Antowan shares her journey balancing pre-med life, managing HS, advocating on TikTok, and her vision for empathetic dermatologic care.

Management 81

Management Dermatology 81

Beauty Launchpad

DECEMBER 5, 2024

Hair Care brand Rahua expert commentary and key insights suggests that consumers are looking for simplified hair and beauty routines that prioritize wellness and cleanliness.

Branding 75

Branding 75

Beautiful With Brains - Skincare

DECEMBER 5, 2024

You know you should NEVER pop a pimple, right? It’s gross. And spreads the infection around. Yuck. But, come on, you’re doing it anyway. Because, it feels SO satisfying. Doesn’t it? And who wants to wait days for pimples to fade away on their own anyway… Well, while I don’t recommend you pop a pimple […] The post How To Pop A Pimple Like A Derm appeared first on Beautiful With Brains.

Oily Skin 52

Oily Skin Skincare 52

Beauty Launchpad

DECEMBER 5, 2024

Together, Booksy and Zowie are empowering hair professionals to streamline their day-to-day business operations with ease.

Innovations 52

Innovations 52

Dermatology Times

DECEMBER 5, 2024

The algorithm demonstrated 81% accuracy, promising fast, reliable, and reproducible assessments for patients.

41

41

Dermatology Times

DECEMBER 5, 2024

Although all observed treatments showed efficacy, the 30 mg dosage of upadacitinib was most successful in relieving itch for atopic dermatitis patients.

Dermatitis 41

Dermatitis Treatments 41

The Dermatology Digest

DECEMBER 5, 2024

Apogee Therapeutics recently hosted its first R&D Day, which featured updates across its entire portfolio. Some of the key highlights related to atopic dermatitis (AD) therapies include: APG777 APG777 is a novel, subcutaneous, extended half-life monoclonal antibody (mAb) targeting interleukin (IL)-13. APG777 demonstrates a 77-day half-life in a 12-month update from the Phase 1 study in healthy volunteers.

Portfolios 74

Portfolios Dermatitis Sustainability Injections 74

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how the role of AI in Hidradenitis Suppurativa and the potential for complex multi-input factors.

36

36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how early recognition of hidradenitis suppurativa coupled with timely initiation of biologic therapies can significantly improve treatment outcomes and prevent disease progression.

Management 36

Management Therapy Treatments 36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how managing patient expectations while implementing combination treatment approaches can optimize outcomes in hidradenitis suppurativa, emphasizing the importance of clear communication about treatment goals and timelines.

Treatments 36

Treatments Management 36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how identifying optimal timing for treatment switches and emerging therapeutic innovations are reshaping the management landscape for hidradenitis suppurativa, with the potential to improve long-term patient outcomes.

Management 36

Management Treatments Innovations 36

Dermatology Times

DECEMBER 5, 2024

James Song, MD, discusses how recent advances in vitiligo treatment, including Janus kinase inhibitors and targeted immunotherapies, are transforming the therapeutic landscape with more effective options for repigmentation and disease management.

Therapy 36

Therapy Management Treatments 36

Dermatology Times

DECEMBER 5, 2024

James Song, MD, discusses how Janus kinase (JAK) inhibitors represent a breakthrough in vitiligo treatment by effectively targeting the immune pathways responsible for depigmentation, offering patients a powerful new therapeutic option with promising repigmentation results.

Treatments 36

Treatments 36

Dermatology Times

DECEMBER 5, 2024

James Song, MD, discusses how clinical trial data demonstrates the risk-benefit profile of vitiligo therapies, with particular focus on balancing potential adverse effects of Janus kinase inhibitors against their proven efficacy in achieving repigmentation.

Safety 36

Safety Therapy Clinic 36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how hidradenitis suppurativa significantly impacts patients' quality of life through chronic pain, skin lesions, and social stigma, while remaining frequently misdiagnosed or diagnosed late due to low disease awareness among healthcare providers.

36

36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how current HS treatments, ranging from topical antibiotics to biologics, show varying degrees of efficacy in managing symptoms, while highlighting the need for individualized treatment approaches based on disease severity and patient factors.

Safety 36

Safety Treatments Management 36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss future innovations in hidradenitis suppurativa (HS) treatment and recommendations for guidelines and support groups.

Innovations 36

Innovations Management Treatments 36

Dermatology Times

DECEMBER 5, 2024

Panelists discuss how artificial intelligence could revolutionize HS diagnosis through automated image analysis, pattern recognition of clinical presentations, and improved early detection capabilities, potentially reducing diagnostic delays.

Treatments 36

Treatments Clinic 36

Dermatology Times

DECEMBER 5, 2024

Researchers found integrating dermatologists into primary care reduces costs and improves diagnostic precision for skin conditions.

31

31